Gilead Sciences reported earnings, leading Bank of America to reiterate a Buy rating.
1 report, 1 independent
Updated Aug 8
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Gilead Sciences reported earnings, leading Bank of America to reiterate a Buy rating.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Gilead Sciences
American company
- Required regulatory filings regarding institutional holdings were made by Gilead Sciences, Inc. with the Securities and Exchange Commission on June 11, 2026.
- A pilot program is underway involving the federal government, Benue State, and Gilead Sciences, with the state participating in the drug supply management.
-
Bank of America
American multinational banking and financial services corporation
Related events
- Bank of America reiterated its Buy rating on Casey's General Stores, communicating the update via a note to TheStreet on September 15, 2026.
- Meta and Tesla faced scrutiny after spending reports, while BofA maintained a Buy rating on Meta stock.
- Bank of America reiterated a 'buy' rating on stock while companies like Starbucks and Dutch Bros Inc operate and compete in the Texas QSR market.
- Bank of America maintained its Buy rating on Novartis shares.
- Bank of America commented on the failed acquisition bids and strategic review outcomes for CooperVision.